The acute respiratory syndrome market was valued at USD 2.96 Billion in 2024, driven by the rising cases of ARDS and acute lung injuries across 8 major markets. The market is anticipated to grow at a CAGR of 5.60% during the forecast period of 2025-2034, with the values likely to reach USD 5.10 Billion by 2034.
Base Year
Historical Year
Forecast Year
The market is poised for growth due to the increasing prevalence of respiratory conditions and advancements in therapeutic options, including biologics and anti-inflammatory drugs, which address critical unmet needs in severe respiratory distress management.
Rising investments in research for targeted ARDS treatments, coupled with innovative drug development focusing on cytokine modulation and immune response regulation, are expected to drive significant market expansion during the forecast period.
The integration of advanced diagnostic technologies, along with supportive government initiatives to combat respiratory diseases, will enhance treatment accessibility and further propel the growth of the market globally.
Acute respiratory distress syndrome (ARDS) arises when inflammation in the lungs leads to fluid accumulation in the tiny elastic air sacs known as alveoli. These air sacs, lined with a protective membrane, are essential for oxygen exchange. However, inflammation damages this membrane, causing fluid to leak into the alveoli. This fluid buildup prevents the lungs from fully expanding, reducing their capacity to fill with air. Consequently, oxygen levels in the bloodstream drop, depriving the body’s organs of the oxygen needed for proper functioning.
Advancements in Cell-Based Therapies to Transform the Treatment Landscape
The rising prevalence of severe ARDS cases and progress in cell-based therapies are key factors driving market growth. In February 2024, MiNK Therapeutics announced promising results from its trial of agenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy for ARDS in critically ill COVID-19 patients. This therapy showed potential to improve outcomes for patients undergoing VV-ECMO (veno-venous extracorporeal membrane oxygenation). As the first immune cell therapy trial in this patient group, agenT-797 represents a major step forward in ARDS management. Its success is expected to stimulate market expansion by fostering confidence in advanced treatment modalities and encouraging further investment in immune-focused therapies.
Surge in Clinical Trials to Meet Rising Acute Respiratory Distress Syndrome Market Demand
The urgent need for effective therapies is a key driver for market innovation. In December 2023, BARDA awarded a multimillion-dollar contract to PPD Development, LP, part of Thermo Fisher Scientific, to conduct a phase 2 clinical trial. Over three years, this trial will evaluate the safety and efficacy of host-directed therapeutics at up to 60 U.S. clinical sites, enrolling 600 hospitalised ARDS patients. This initiative aims to advance critical therapeutic options and highlights a growing focus on host-directed treatments. The trial is poised to drive significant market growth by fostering innovation, accelerating the development of novel therapies, and addressing unmet needs in ARDS management.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Market Share Based on Drug Class to Witness Significant Growth
In the segmentation by drug class, the market is divided into vasoconstrictors, bronchodilators, sedatives/paralytics, surfactants, steroids, antibiotics, and others. This segment holds a significant share owing to its essential role in managing respiratory distress symptoms effectively.
The United States dominates the market due to its advanced healthcare infrastructure, high prevalence of respiratory disorders, and significant investments in medical research and development. The presence of leading pharmaceutical companies and the robust adoption of innovative treatments and devices further strengthen its position. Additionally, government initiatives to combat respiratory diseases and an established emergency care network drive market growth. The United States leads in patient accessibility to cutting-edge therapies, making it the largest regional contributor to the market.
The key features of the market report comprise clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Established in 1896 and headquartered in Basel, Switzerland, F. Hoffmann-La Roche Ltd. is a global leader in pharmaceuticals and diagnostics. In the acute respiratory distress syndrome (ARDS) market, Roche focuses on developing innovative therapies aimed at modulating the immune response and reducing inflammation to improve patient outcomes. Their extensive research and development efforts contribute significantly to advancing ARDS treatment options.
Founded in 1999 and based in Cambridge, United Kingdom, AstraZeneca plc is a multinational pharmaceutical company specialising in the discovery and development of prescription medicines. Within the ARDS market, AstraZeneca is actively engaged in researching and developing treatments that target underlying causes of respiratory distress, including anti-inflammatory agents and therapies aimed at enhancing lung function. Their commitment to respiratory health positions them as a key player in addressing ARDS challenges.
Headquartered in Brentford, United Kingdom, and established in 2000, GSK plc is a global healthcare company with a strong focus on pharmaceuticals, vaccines, and consumer healthcare products. In the ARDS market, GSK is involved in developing therapeutic solutions that aim to modulate the immune response and reduce lung inflammation, thereby improving patient survival rates and recovery times. Their research initiatives are pivotal in advancing ARDS treatment modalities.
Founded in 1988 and headquartered in Tarrytown, New York, USA, Regeneron Pharmaceuticals, Inc. is a leading biotechnology company known for its innovative approach to drug development. Regeneron focuses on creating monoclonal antibodies and other biologic therapies designed to mitigate the severe inflammatory responses associated with ARDS, aiming to improve clinical outcomes for affected patients. Their cutting-edge research contributes to expanding the therapeutic landscape for ARDS.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Novartis AG, Faron Pharmaceuticals Oy, Bayer AG, AbbVie Inc., Veru Inc., and Eli Lilly and Company.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share